Medical Condition News

RSS

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor, NBI-98854.

24 Jun 2011

AMT receives CHMP opinion on Glybera Marketing Authorisation Application

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera as a potential therapy for Lipoprotein Lipase Deficiency.

24 Jun 2011

Hunger hormone likely to cause stress-linked complex eating behaviors

We are one step closer to deciphering why some stressed people indulge in chocolate, mashed potatoes, ice cream and other high-calorie, high-fat comfort foods. UT Southwestern Medical Center-led findings, in a mouse study, suggest that ghrelin - the so-called "hunger hormone" - is involved in triggering this reaction to high stress situations.

24 Jun 2011

Millennium reports ongoing MLN8237 Phase II study results on non-Hodgkin lymphoma

Millennium: The Takeda Oncology Company today announced the presentation of results from an ongoing Phase II study of MLN8237, an investigational Aurora A kinase inhibitor, in patients with relapsed/refractory aggressive B-cell and T-cell non-Hodgkin lymphoma.

24 Jun 2011

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.

24 Jun 2011

Anticholinergic drugs might increase risk of cognitive impairment, death in older people

A side effect of many commonly used drugs appears to increase the risks of both cognitive impairment and death in older people, according to new research led by the University of East Anglia.

24 Jun 2011

Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has expanded its pipeline of proprietary zinc-based therapies to include a planned Phase IIb clinical trial of patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.

24 Jun 2011

Potential new approach for treating myelofibrosis

A new study conducted by a team of researchers at Boston University School of Medicine (BUSM) sheds light on a possible new approach to treat the bone marrow disease known as myelofibrosis by inhibiting an enzyme that connects extracellular fibers.

24 Jun 2011

Scientists discover sleep switch in fruit fly's brain

Rather than count sheep, drink warm milk or listen to soothing music, many insomniacs probably wish for a switch they could flick to put themselves to sleep.

24 Jun 2011

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that its Taiwanese partner, Orient Europharma, has concluded the Site Initiation Visit for the first Taiwanese clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy. The first center is called Shin Kong Wu Ho-Su Memorial Hospital and is located in Taipei, Taiwan.

24 Jun 2011

Researchers discover new mechanism for origin of Barrett's esophagus

Researchers have discovered a new mechanism for the origin of Barrett's esophagus, an intestine-like growth in the esophagus that is triggered by chronic acid reflux and often progresses to esophageal cancer.

24 Jun 2011

FDA grants Orphan Drug Designation for Accentia's Revimmune to treat two autoimmune diseases

Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia.

24 Jun 2011

Reductions in obesity-related medical costs offset cost of gastric banding surgery within 2.25 years

Allergan, Inc. today announced a new study published in the peer-reviewed journal Surgery for Obesity and Related Diseases that found the cost of a gastric banding weight-loss surgery procedure, such as Allergan's LAP-BAND Adjustable Gastric Banding System, was offset by reductions in obesity-related medical costs within 2.25 years for surgery eligible patients with diabetes, and within four years of the procedure for all surgery eligible patients.

23 Jun 2011

Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals

Arno Therapeutics, Inc. announced today that its Phase II clinical study of AR-67 has met pre-defined interim goals for patients with glioblastoma multiforme (GBM) who were not previously treated with Avastin and will continue toward completion.

23 Jun 2011

Majority of cancers are due to epigenetic influences

Dr. Ajay Goel, Ph.D., Director of Epigenetics and Cancer Prevention at the Gastrointestinal Research Center at Baylor University Medical Center in Dallas, TX, has announced plans for a series of upcoming studies to continue to unlock the mechanisms by which curcumin prevents cancer via its influence on epigenetic activity.

23 Jun 2011

FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, announced today that their lead program, SBC-102, an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, currently in clinical trials, has been granted fast track designation by the U.S. Food and Drug Administration (FDA).

23 Jun 2011

Medical Condition News

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

AMT receives CHMP opinion on Glybera Marketing Authorisation Application

Hunger hormone likely to cause stress-linked complex eating behaviors

Millennium reports ongoing MLN8237 Phase II study results on non-Hodgkin lymphoma

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Anticholinergic drugs might increase risk of cognitive impairment, death in older people

Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS

Potential new approach for treating myelofibrosis

Scientists discover sleep switch in fruit fly's brain

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

Researchers discover new mechanism for origin of Barrett's esophagus

FDA grants Orphan Drug Designation for Accentia's Revimmune to treat two autoimmune diseases

Reductions in obesity-related medical costs offset cost of gastric banding surgery within 2.25 years

Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals

Majority of cancers are due to epigenetic influences

FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency

Spinal manipulative therapy provides minor but significant benefits for patients with chronic low back pain

New proteomics-based approach to analyze bone quality

Resveratrol may make old age more tolerable, but not prevent it

FDA grants Fast Track designation for Repligen's RG3039 to treat Spinal Muscular Atrophy

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News